Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.: Where Does Claim Construction Go From Here?

Intellectual Property Today
March 2015

Dominick Conde and Dennis Aeling analyze the Supreme Court’s January 20th, 2015 decision in Teva Pharmaceuticals v. Sandoz, which overturned the Federal Circuit’s de novo standard of review for district court claim constructions, and its implications on future patent litigations.

View Attachment (PDF)